

## CURRICULUM VITAE

**Nancy Jean M. Vuckovich Bohannon, MD, FACP, FACE**

**Business Address:**

Monteagle Medical Center  
1580 Valencia Street, Suite 109  
San Francisco, CA 94110  
(415) 648-7622  
[www.SugarNancy.com](http://www.SugarNancy.com)

**Tax I.D. Number:**

94-2534677

**Academic Titles:**

Director of Clinical Research  
Cardiovascular Risk Reduction Program  
Saint Luke's Hospital  
San Francisco, CA 2004

Touro University Adjunct Associate  
Clinical Professor 2001

Associate Clinical Professor of Medicine and  
Family and Community Medicine, UCSF  
University of California, San Francisco  
School of Medicine 1998-

Clinical Professor, NCP Vocational  
College of Nursing 1995-

Adjunct Assistant Professor of Medicine,  
Baylor College of Medicine 2000 - 2009

**Birthplace:**

Cherry Point, North Carolina

**Date:**

November 25, 1947

**Personal:**

Married - Richard Anderson Bohannon MD, January 19, 1974  
Child - Robert John Bohannon, born July 22, 1978

**Education:**

- 1965 - 1966 California State College at Fullerton  
Fullerton California
- 1966 - 1968 University of Illinois (Champaign-Urbana)  
Urbana, Illinois  
BS with Honors
- 1968 - 1970 Student Work-Study Program  
Animal Cancer Research  
University of California Veterinary School  
Davis, CA
- 1971 American Cancer Society Student  
Fellowship  
Cancer Research Institute  
University of California, San Francisco
- 1968 - 1972 University of California  
Davis, California  
M.D.

**Postgraduate Training:**

- 1972 - 1973 *Internship:*  
Straight Internal Medicine  
Children's Hospital, San Francisco, CA
- 1973 - 1974 *Residency:*  
Internal Medicine  
Children's Hospital, San Francisco, CA
- 1974 - 1975 *Fellowship:*  
San Francisco Diabetes Association  
Clinical Fellowship  
Metabolic Research Unit  
University of California, San Francisco, CA
- 1975 - 1976 *Fellowship:*  
Dorothy Frank Research Fellowship of  
San Francisco Diabetes Association  
Metabolic Research Unit  
University of California, San Francisco, CA

## **PROFESSIONAL ORGANIZATIONS**

American Medical Association, 1976 - present

California Medical Association

- 1) Delegate to the California Medical Association, 1982 - 1985
- 2) Member, Committee on Scientific Assembly, 1981 - 1987
- 3) Chairman, Committee on Scientific Assembly, 1983 - 1987
- 4) Member, Scientific Board of California Medical Association, 1983 - 1987
- 5) Member, Reference Committee on Federal Health Care Issues, 1981, 1982

San Francisco Medical Society

- 1) Board of Directors, 1982 - 1984
- 2) Speaker's Bureau for Health Related Matters, 1980 - Present
- 3) Member, Administrative Board of Directors, Irwin Memorial Blood Bank, 1982 - 1984

American College of Physicians

- 1) Associate, 1976 - 1981
- 2) Member since 1981
- 3) Fellow since 1984

American Society of Internal Medicine, Member 1974 -

Skyline Medical Association

- 1) Member, 1988
- 2) Exec. Comm., 1993 - present
- 3) President-elect, 1994
- 4) President, 1995-1996

California Society of Internal Medicine

- 1) Delegate to Annual Meeting, 1978, 1980, 1982, 1984, 1986, 1988, 1989, 1997
- 2) Membership Committee, 1981 - 1983
- 3) Annual Meeting Local Arrangements Committee, 1988

San Francisco, Society of Internal Medicine

- 1) Council Member, 1978 - 1992
- 2) Secretary-Treasurer, 1981 - 1982
- 3) President, 1983 - 1984

Interstate Postgraduate Medical Association of North America

- 1) President Elect, 1995 - 1996
- 2) President, 1996-1997

California Pan American Medical Society

- 1) President, 2000 - 2003,
- 2) Board of Directors, 2003 - 2006

American Diabetes Association

Professional Section, 1978 - Present

California Affiliate

- 1) Chairman, Committee on Public Education, 1987 - 1989

San Francisco Chapter

- 1) Member, Board of Directors, 1976 - 1980
- 2) Vice President, 1979
- 3) Advisory Board, 1982
- 4) Speaker's Bureau, 1976 - Present
- 5) President, 1989

Northern California Professional Diabetes Association 1978-Present

Vice President, 1983

American Assn. Of Clinical Endocrinologists

- 1) Member since 1991
- 2) Fellow since

California Chapter, American Assn. of Clinical Endocrinology

- 1) Board of Directors, 2006 - present
- 2) Secretary, 2010 - 2012
- 3) Treasurer, 2012 -

American Federation for Clinical Research, Member, 1982 - present

International Diabetes Federation, 1991 - present

American Heart Association Council on Atherosclerosis, 1991 - present

National Grave's Disease Foundation, 1991 - present

Board of Directors Dance Out Diabetes, 2011 - 2013

## **EDITORIAL AND REVIEW BOARDS**

Reviewer for Expert Opinion on Pharmacotherapy, 2003

Reviewer for Patient Care (Diabetes Case and Comment), 1985 - present

Editorial Review Panel, Postgraduate Medicine, 1987 - present

Editorial Board of Diabetes Forecast, January 1993 - December 1995

Professional Advisory Panel, Patient Care, 1994

Reviewer for American Society of Health System Pharmacists Drug Information, 1996 - 1997

Editorial Board for Primary Care Reports: The Practical Journal for Family Physicians, 1996 - present

Reviewer for Endocrine Practice, 1998 - present

Editorial Advisory Board for American Health Consultants: Diabetes Management, 1998 -

Reviewer for Diabetes Care, 1999 - present

Reviewer for Clinician Review, 2002

Reviewer for Diabetes and Its Complications, 2004

Reviewer for Expert Review of Medical Devices, 2004

Editorial Board Member for Insulin, 2005 - 2010

Reviewer for Pharmacy and Therapeutics (P&T) Journal, 2006

## **PUBLICATIONS**

1. Klock J, and Vuckovich N.: Current Status of Bone Marrow Transplantation. *Oncology* 29: 127-151, 1974.
2. Gerich JE, Tsalikian E, Lorenzi M, Schneider V, Bohannon NJ, Gustafson G, and Karam JH: Normalization of Fasting Hyperglucagonemia and Excessive Glucagon Responses to Intravenous Arginine in Human Diabetes Mellitus by Prolonged Infusion of Insulin. *J. Clin. Endocrinol. Metab.* 41: 1178-1180, 1975.
3. Bohannon NJ, Lorenzi M, Gerich HD, and Karam, JH: Plasma Glucagon Suppression by Phenformin in Man. *Diabetes* 24 (Suppl. 2): 428, 1975.
4. Lorenzi M, Bohannon NJ, Tsalikian E, Hane S, Gerich JE, Karam JH, and Forsham PH.: Intact Dopaminergic Receptors for Growth Hormone and Prolactin Secretion in Insulin-Dependent Diabetics. *Clinical Research* 24: 110A, 1976.
5. Gerich J, Lorenzi M, Tsalikian E, Schneider V, Bohannon NJ, Karam JH, and Forsham PH: Selective Pancreatic A-cell Insensitivity to Glucose in Human Diabetes Mellitus: Evidence for a Defective Glucoreceptor. *Clinical Research* 24: 155A, 1976.

6. Bohannon NJ, Karem J, Lorenzi M, Gerich J, and Forsham P.: Plasma Glucagon Levels After Tolbutamide or Phenformin in Insulin-Dependent Diabetics. *Clinical Research* 24: 154A, 1976.
7. Lorenzi M, Tsalikian E, Bohannon NJ, Gerich JE, Karem JH, and Forsham PH: Evidence Against Dompaminergic Modulation of Glucagon and Insulin Release in Man. Program of the 58th Annual Meeting of the Endocrine Society, San Francisco, California, June 23-25, 1976, p. 229.
8. Meyer EJ, Lorenzi M, Bohannon NJ, Amend W, Feduska JH, Salvatierra O, and Forsham PH: Use of Insulin Infusion in Diabetic Renal Transplantation. Program of the 57th Annual Meeting of the American College of Physicians, Philadelphia, Pennsylvania, April 5-8, 1976 (Abstract No. 11).
9. Lorenzi M, Tsalikian E, Bohannon NJ, Gerich JE, Karam JH, and Forsham PH: Differential Sensitivity of Pancreatic Glucagon to L-Dopa and Apomorphine in Man: Evidence Against a Direct Dopaminergic Mechanism of Stimulation. Program of the 5<sup>th</sup> International Congress of Endocrinology, Hamburg, Germany, July 18, 1976: 24: 341.
10. Gerich JE, Lorenzi M, Tsalikian E., Bohannon NJ, Schneider V, Karam JH, and Forsham PH: Effects of Acute Insulin Withdrawl and Administration of Plasma Glucagon Responses to Intravenous Arginine in Insulin-Dependent Diabetic Subjects. *Diabetes* 25: 855-960, 1976.
11. Gerich J, Lorenzi M, Tsalikian E, Bohannon NJ, Brooks R, Meyer J, Schultz T, Spencer M, and Forsham PH: Prolonged Intravenous and Subcutaneous Somatostatin in Treatment of Human Diabetes. *Diabetes* 25 (Suppl. 1): 340, 1976.
12. Tsalikian E, Dunphy T, Bohannon NJ, Lorenzi M, Gerich J, and Karam JH: Suppression of Plasma Glucagon During Chronic Sulfonyleurea Therapy in Adult-Onset Diabetes. *Diabetes* 25 ( Supplement 1): 387, 1976.
13. Tsalikian E, Dunphy TW, Bohannon NJ, Lorenzi M, Gerich JE, Forsham PH, Kane JP, and Karam JH: The Effect of Chronic Oral Antidiabetic Therapy on Insulin and Glucagon Responses to a Meal. *Diabetes* 26: 314-321, 1977.
14. Goldberg ML, Bohannon NJ, Brooks RM, Tsalikian E, Lorenzi M, and Forsham, PH: The Effects of Insulin and Hyperglycemia on Plasma Cyclic Nucleotide Levels in Juvenile Onset Diabetes. *Diabetes* 26: 936-943, 1977.
15. Bohannon NJ, Karam JH, Lorenzi M, Gerich JE, Matin SB, and Forsham PH: Plasma Glucagon Suppression by Phenformin in Man. *Diabetologia* 13: 503-508, 1977.
16. Lorenzi M, Tsalikian E, Bohannon NJ, Gerich JE, Karam JH, and Forsham PH: Differential Effects of L-Dopa and Apomorphine on Glucagon Secretion in Man. *J. Clin. Endocrinol. Metab.* 45: 1154-1158, 1977.
17. Gerich J, Davis J, Lorenzi M, Bohannon NJ, and Cryer P: Interaction of Catecholamines and Glucagon in Glucose Counterregulation. *Diabetes* 26 (Supplement 1) 384, 1977.
18. Lorenzi M, Schmitt JK, Bohannon NJ, Tsalikian E, Karam JH, and Forsham PH: Intravenous Dopamine Stimulates Growth Hormone Secretion in Diabetic Subjects: A Clue to Blood-Brain Barrier Abnormalities. *Diabetes* 26 (Suppl. 1): 378, 1977.
19. Lorenzi M, Tsalikian E, Bohannon NJ, Schmitt J, Gerich J, and Karam JH: Dopamine During Alpha-and-Beta-Adrenergic Blockade in Man: Effect of Plasma Glucagon, Insulin, Prolactin, and Growth Hormone. Program of the 59th Annual Meeting of the Endocrine Society, Chicago, Illinois, June 8-10, 1977, P. 135.
20. Feldman EC, Bohannon NJ, and Tyrrell JB: Plasma Adrenocorticotropin Levels in Normal Dogs. *American Journal of Veterinary Research* 38: 1643-1645, 1977.
21. Bohannon NJ, Karam JH, and Forsham PH: Comparison of Prolonged Responses to Fructose, Sucrose, and Glucose Feeding. Presented at the Annual Meeting of the American Diabetic Association, Los Angeles, California, October 11, 1977. (Program, p. 20).

22. Schmitt J, Lorenzi M, Gerich H, Bohannon NJ, Karam JH, and Forsham PH: Effect of Phentolamine on Somatostatin's Action in Man. *Clinical Research* 26: 131A, 1978.
23. Lorenzi M, Schmitt J, Tsalikian E, Bohannon NJ, Gerich J, Karam JH, and Forsham PH: Dose-Response Curves for Insulin and Glucagon Suppression by Somatostatin in Man. *Clinical Research* 26: 159A, 1978.
24. Bohannon NJ, Karam JH, and Forsham PH: Advantages of Fructose Ingestion Over Sucrose and Glucose in Humans. Presented at the Annual Meeting of the American Diabetes Association, Boston, Massachusetts, June, 1978. *Diabetes* 27 (Supplement 2): 438, 1978.
25. Lorenzi M, Karam JH, Tsalikian E, Bohannon NJ, Gerich JE, and Forsham PH: Dopamine During Alpha- and Beta-Adrenergic Blockade in Man: Hormonal, Metabolic and Cardiovascular Effects. *J. Clin. Invest.* 63:310, 1979.
26. Schmitt J, Bohannon NJ, Burns A, and Forsham PH: Comparative Effects of Indomethacin and Ibuprofen on the Response of Arginine in Man. *Diabetes* 28: 440, 1979.
27. Meyer EJ, Lorenzi M, Bohannon NJ, Amend W, Feduska NJ, Salvatierra O, and Forsham PH: Diabetic Management by Insulin Infusion During Major Surgery. *American Journal of Surgery* 137: 323, 1979.
28. Schmitt JK, Lorenzi M, Gerich JH, Bohannon NJ, Karam JH, and Forsham PH: Phentolamine and the Action of Somatostatin in Man. *J. Clin. Endocrinology Metab.* 48:880, 1979.
29. Bohannon NJ, Karam JH, and Forsham PH: Endocrine Responses to Sugar Ingestion in Man. *J. Am. Dietetic Assn.* 76:6, 1980.
30. Gerich J, Davis J, Lorenzi M, Rizza R, Bohannon NJ, Karam JH, Lewis S, Kaplan R, Schultz T, and Cryer P: Hormonal Mechanisms of Recovery from Insulin-Induced Hypoglycemia in Man. *Am. J. Physiol.* 236 (4), E380, 1979.
31. Deftos LJ, Lorenzi M, Bohannon NJ, Tsalikian E, Schneider V, and Gerich JE: Somatostatin does not suppress Plasma Parathyroid Hormone. *J. Clin. Endocrinol. Metab.* 43: 205, 1976.
32. Schmitt JK, Bohannon NJ, Lorenzi M, Karam JH, and Forsham PH: Arginine-Stimulated Fall in Free Fatty Acids as an Index of Insulin Reserve in Diabetics. *Clinical Research* 28: 26A, 1980.
33. Schmitt JK, Bohannon NJ, Karam JH, Forsham PH: Arginine-Stimulated Fall in Free Fatty Acids as an Index of Insulin Reserve in Diabetics. *Diabetes* 29: 68A, 1980.
34. Bohannon NJ: Anabolic Steroid Abuse and Impotence. *Medical Aspects of Human Sexuality.* 14: 60, 1980.
35. Klonoff DC, Young CW, Chan ETY, Burns A, Bohannon NJ, Karam JH, Forsham PH: Advantages of Fructose as a Dietary Sweetener in Insulin-Dependent Diabetes. *Clin. Res.* 29 (1): 55A, 1981.
36. Bohannon NJ, Reitz RE, Hauer SD, Wang CA: The Management of Acute Hyperparathyroidism in the Community Hospital. *JAMA:* 246 (12) 1334, 1981.
37. Bohannon NJ, Zilbergeld BV, Bullard DG, and Stoklosa JM: Treatable Impotence in Diabetics. *Western Journal of Medicine* 136: 6-10, 1982.
38. Bohannon NJ, Karam JH, Grodsky GM: Stimulatory Effects of Tolbutamide Infusion on Plasma Glucagon in Insulin-Dependent Diabetic Subjects. *J. Clin. Endo and Metab.* 54:459-462, 1982.
39. Bohannon NJ: Newer Forms of Insulin. *West J. Med.* 139: 115-116, 1983.
40. Bohannon NJ: Anorexia Nervosa. *J. Osteo. Med.* 1: 28-36, 1987.
41. Bohannon NJ: Large Phosphate Shifts During Therapy for Hyperglycemia. presented at Northern California Annual Meeting of American College of Physicians, Monterey, California, Oct.18,1987.
42. Bohannon NJ, Torfs CP, van den Berg BJ, Okerlund MD: Thyroid Disease in Families of Proband with IDDM. Presented at International Diabetes Federation meeting, Sydney, Australia November 1988.

43. Torfs CP, van den Berg BJ, Bohannon NJ, Caro MB, Okerlund MD: Lack of Spouse Concordance for Thyroid Antibodies Suggests that Shared Environmental Factors have no Effect on the Expression of Autoimmune Thyroid Diseases. Submitted.
44. Bohannon NJ: Diabetes in the Elderly. *Postgraduate Medicine*. 84: 283-295, 1988.
45. Bohannon NJ: Gestational Diabetes. *Diabetic Management Issues for the Educator. Synopses of Selected Presentations*. AADE, Dallas.
46. Bohannon NJ: Hypophosphatemia in Treatment of Hyperglycemia. *Archives of Internal Medicine* 149:1423-1426,1989.
47. Bohannon NJ: Diabetes Control and the Drugs That Can Disturb It, *Senior Patient*. 33-36, May 1990.
48. Bohannon NJ: Diabetes and Calcium Channel Blockers (letter), *Senior Patient*, August 57-58, 1990.
49. Bohannon NJ: Diabetic Ketoacidosis Triggered by Typhoid Fever in a Type II Diabetic, *Infections in Medicine* 9: 45-52, 1992.
50. Bohannon NJ: Lipid Metabolism in Type II Diabetes, *Postgraduate Medicine* 92:105-113, 1992.
51. Bohannon NJ ed, Davidson MB, Riddle MC: Symposium on Non-Insulin Dependent Diabetes Mellitus, *Postgraduate Medicine* 92: 69-113, 1992.
52. Bohannon NJ: Effective Use of Insulin, *Postgraduate Medicine* 95: 52-67, 1994.
53. Bohannon NJ: Type II Diabetes, *Primary Care Reports* 1(9): 65-74, May 1995.
54. Torfs CP, Bohannon NJ, van den Berg BJ: Spousal Concordance of Autoimmune Thyroid Disease (submitted to *Endocrine Practice*, 1995).
55. Tomada JA, Bohannon NJ, Potts R: Measurement of Blood Glucose in Diabetic Subjects Using Non-invasive Transdermal Extraction , *Nature Medicine*, 1 (11): 1198-1201, November, 1995.
56. Bohannon NJ: Type II Diabetes : Tips For Managing Your Older Patients, (Part I) *Geriatrics*, 51 (3): 28-35, March 1996.
57. Bohannon NJ: Type II Diabetes : Tips For Managing Your Older Patients, (Part II) *Geriatrics*, 51 (4): 28-35, April 1996.
58. Bonow R O, Bohannon NJ, Hazzard W: Risk Stratification in Coronary Artery Disease and Special Populations, *American Journal of Medicine* 101 (Supp. 4A): 17S-24S, 1995.
59. Winslow E, Bohannon NJ, Brunton SA, Mayhew HE: Lifestyle Modification: Weight Control, Exercise, and Smoking Cessation, *American Journal of Medicine* 101 (Supp. 4A): 25S-33S, 1996.
60. Bohannon NJ: Benefits of Lispro Insulin , *Postgraduate Medicine* 101 (2):73-80, 1997.
61. Faro S, Apuzzio J, Bohannon NJ, Elliott K, Martens MG, Mou SM, Phillips-Smith LE, Soper DE, Strayer A, Young RL: Treatment Considerations in Vulvovaginal Candidiasis, *The Female Patient*, 22, March 1997.
62. Bohannon Nancy JV: Management of Vulvovaginal Candidiasis in the Diabetic Patient, *Diabetes Care* 21 (3): 451-456, 1997.
63. Ginsberg B, Bohannon N, et. al: In Vivo Studies of a Non-Invasive Glucose Monitor in Patients with Diabetes (abstract presented) *American Diabetes Assn. meeting*, June, Diabetes, 1998.
64. Bohannon, Nancy J.V.: Coronary Heart Disease and Diabetes, *Postgraduate Medicine* 105(2):65-80, 1999.
65. Bohannon N: Insulin Delivery Using Pen Devices, *Postgraduate Medicine* 106 (5):57-68, 1999.
66. Bohannon N, Streja L.;Effectiveness of Terbinafine Therapy for Toenail Onychomycosis in Persons with Diabetes (abstract presented *American Diabetes Association meeting*, June 2000) 49 (S1): 805P, 2000.
67. Feldman B, McGarraugh G, Heller A, Bohannon N, Skyler J, DeLeeuw E, Clarke M : FreeStyle: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing, *Diabetes Technology & Therapeutics* Vol 2 (2):221-229, 2000.



68. Bohannon NJ, Fishman I: Comparison of Efficacy and Patient Preference for Lispro versus Humulin Regular Insulin and Delivery by a 1.5 mL Pen Injection Device (in preparation 1999).
69. Bohannon NJ, Ohannesian JP, Burdan AL, Holcombe JH, Zagar A: Patient and Physician Satisfaction with the Humulin®/Humalog® Pen, a new 3.0-mL Prefilled Pen Device for Insulin Delivery, *Clinical Therapeutics* Vol 22, No 9 (1049-1067), 2000.
70. Bohannon NJ: Type 1 versus type 2 diabetes still a useful distinction? *Postgraduate Medicine* 100(2):23-24, 2001.
71. Bohannon NJ: Treating dual defects in diabetes: Insulin resistance and insulin secretion *American Journal of Health-System Pharmacy™* Vol 59, Supplement 9 (9-13), December 1, 2002.
72. Bohannon N., Insulin therapy for reducing cardiovascular risk in patients with type 2 diabetes. *Clin Cornerstone*. 2003; Suppl 4:S21-7. Review.
73. Bohannon NJ: Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. *Postgraduate Medicine*, Vol.113, No.6 (39-54), June 2003.
74. Quattrin T, Belanger A, Bohannon N, Schwartz S: Efficacy and Safety of Inhaled Insulin (Exubera) Compared to Subcutaneous Insulin Therapy in Patients with Type 1 Diabetes: Results of a 6-month Randomized, Comparative Trial *Diabetes Care*, Vol. 27:2622-2627, 2004.
75. Bohannon N: Insulin Therapy for Reducing Cardiovascular Risk in Patients with Type 2 Diabetes, *Clinical Cornerstone*, Supp.4, S21-27, November 2003.
76. Bohannon N: Targeting pre and Post prandial Glucose Levels in Clinical Practice, *Type 2 Diabetes Digest*, Volume 8, No. 4, November 2004.
77. Deepak L, Steg G, Ohman E, et al: International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis, *JAMA*, Vol. 295, No.2, Jan 11, 2006. (Contributing author: Nancy Bohannon).
78. Cefalu WT, Bohannon NJ, Edwin Fineberg S, Teeter JG, Schwartz PF, Reis JM, Krasner AS., Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of continuous therapy. *Curr Med Res Opin*. 2008 Nov;24(11):3073-83. Epub 2008 Oct 14.
79. Bohannon NJ: Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice, *Postgraduate Medicine*, Volume 121, Issue I, January 2009.
80. Rosenfeld CR, Bode BW, Bohannon NJ, et al: Clinical Practice Improved Glycemic Control in Type 2 Diabetes Patients Using The V-GO™ As Insulin Delivery Device, *AACE 19th Annual Meeting and Clinical Congress*, Poster # 244.
81. Gavin J, Bohannon NJ: A Review of the Response to Oral Antidiabetes Agents in Patients with Type 2 Diabetes, *Postgraduate Medicine*, Volume 122, Issue 3, May 2010.
82. Anhalt H, Bohannon NJ: Insulin Patch Pumps: Their Development and Future in Closed-Loop Systems, *Diabetes Technology & Therapeutics*, Volume 12, Supplement 1, 2010.
83. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. *Lancet*. 2010 Aug 14;376(9740):517-23.
84. Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molitch M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle RL, Dreon D, Tan M: Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. *Diabetes Technol Ther*; 2011 Oct; 13(10):1031-7.

85. Rosenfeld CR., Bohannon NJ, Bode B, Kelman AS, Mintz SN, Schorr AB, Sandberg MI, Nambi, S, Agarwala SK, Leicdhter SB, Larrabee B, Shi L, Strange P: The V-Go Insulin Delivery Device Used In Clinical Practice:Patient Perception and Retrospective Analysis of Glycemic Control, *Endocrine Practice*, Vol 18 No.5 September/October 2012.
86. Bohannon, NJ: Individualized Treatment of Type 2 Diabetes Mellitus Using Noninsulin Agents: Clinical Consideration for the Primary Care Physician, *Postgraduate Medicine*, Volume 124, Issue 4, July 2012.
87. Bohannon NJ, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molitch M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle RL, Dreon D, Tan M: Comparison of a Novel Insulin Bolus\_Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study, *Diabetes Technology and Therapeutics*, Volume 12, Number 10, 2011.
88. Gaziano JM, Cioncotta AH, Vinik A, Blonde L, Bohannon JV, Scranton R: Effect of Bromocriptine\_QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects, *Journal of the American Heart Association*, 2012,1:doi:10.1161/JAHA.112.002279, online version <http://jaha.ahajournals.org/content/1/5/e002279>
89. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwieters ML, Day, W, : Effects of low-dose, controlled-release, phentermine plus Topiramate combination on weight and associated comorbidities in overweight and obese adults (CONAUER): a randomized, placebo-controlled, phase 3 trial, *The Lancet*, Volume 377, Issue 9774, Pages 1341-1352, 16 April 2011. Contributor: Bohannon NJ.
90. Tan M, Bohannon NJ, Bergenstal R, Brunelle RL, Dreon D, Kruger D, Molitch M, Strowig S, Whitehouse F, Zraick V: Safety Profile of Finesse Insulin Bolus-Patch Compared with Pen/Syringe Delivery Devices in Adults with Diabetes Mellitus: Abstract.
91. Gaziano JM, Cincotta AH, Vinik A, Blonde L, Bohannon N, Scranton R., Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. *J Am Heart Assoc*. 2012 Oct;1(5):e002279. Epub 2012 Oct 25.
92. Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM., Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. *Endocr Pract*. 2012 Nov-Dec;18(6):931-43. . Erratum in: *Endocr Pract*. 2013 Jan-Feb;19(1):179.
93. Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwieters M, Troupin B, Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Day WW. *Diabetes Care*. 2014 Apr;37(4):912-21. Epub 2013 Oct 8.

## RESEARCH AND CLINICAL TRIALS

1. Evaluation of Human Insulin, Eli Lilly, 1982 - 1983, Phase III.
2. Human Insulin Clinical Trials Prior to Release, 1983, Phase III.
3. Evaluation of Cimetidine on Parathyroid Hormone and Calcium Levels in Normal Control Population, 1983 - 1986.
4. The Efficacy and Safety of Glipizide in Patients with Non-Insulin Dependent Diabetes Mellitus Previously Treated with Insulin, 1984 - 1985, Phase IV.
5. Study of Cimetidine in Hyperparathyroidism Collaborating with Janice Sherwood, M.D., 1983 - 1987.
6. Islet Cell Antibodies in 1st Degree Relatives of Type I Diabetics Collaborating with George Eisenbarth MD, Joslin Clinic, and Stuart Soeldner MD, Univ. of Calif./Davis, 1984 - present.

7. Study of Autoimmune Antibodies in Families of patients with Autoimmune Thyroid Disease or Type I Diabetes Collaborating with Claudine Torfs PhD, Berkeley, and William Riley MD, Univ. of Florida, 1985 - present.
8. Study of Thyroid Antibodies in Conjugal Couples. Collaborating with Claudine Torfs, PhD, 1985 - present.
9. Study of Antithyroid Antibodies in Families With Type I Diabetics Collaborating with Claudine Torfs, PhD, 1985 - present.
10. Study of Thyroid Antibodies in Families With Thyroid Disease Collaborating with Claudine Torfs, PhD, 1985 - present.
11. Glucotrol Post-Introduction Evaluation, 1985, Phase IV.
12. Sorbinyl Aldose Reductase Inhibitor In Diabetic Complications, 1985 - 1987 (compassionate protocol).
13. Tenoretic Evaluation Program: A Study in Post-Introduction Surveillance of a New Antihypertensive Drug, January, 1986, Phase IV.
14. One Touch Early Trials Program, May 1988.
15. Cholestech evaluation of LDX HDL analyzer, November 1990.
16. Terazosin Hypertension Experience Trial, Phase IV 1990.
17. Hypertensive Mid-Life Male Clinical Evaluation Phase IV trial, 1991.
18. Dyna Circ Assessment Trial Analysis Phase IV trial, 1991.
19. Cholestech evaluation of LDX triglyceride analyzer, 1991.
20. Prosom Evaluation Program, Phase IV, 1992.
21. Dyna Circ Dynamics trial in Special Populations, Phase IV, 1992.
22. Sandoz Fluvastatin Phase III, 1993.
23. Insomnia Treatment Study, Upjohn, Phase IV, 1993.
24. Lilly IOAH Insulin Analog Protocol, Global Phase II and III, 1993.
25. Satellite site for The Diabetes Prevention Trial of Type I Diabetes (DPT-I), affiliated with Stanford University Research Center, 1994 - current.
26. Lilly Lispro study F3Z-MC-IOBX "Insulin Lispro vs. Humulin R Delivered in 1.5 mL Pen." Phase III, 1994 - 1995, Lilly.
27. Evaluation of Glucose Determinations from Venous Blood and Fluid Collected by Iontophoresis, Cygnus Therapeutic Systems, Developmental Studies, 1994.
28. Multicenter Open-Label Study of Terbinafine, Sandoz, Phase III, 1995 -
29. A Placebo-Controlled Safety and Efficacy Study of Pimagedine in Patients with Type II Diabetes Mellitus and Overt Diabetic Nephropathy. Marion Merrell Dow, Phase II and III, 1995.
30. P.R.O.T.E.C.T. Precose: Resolution of Optimal Titration to Enhance Current Therapies trial. Phase III-IV, 1995 -
31. Protocol for a randomized, double-blind, placebo controlled, cross-over study of the analgesic efficacy and safety of topical lidocaine patches and lidocaine gel in painful diabetic neuropathy. Phase II-III. Hind Health Care, Inc. 1996.
32. A double blind randomized placebo-controlled study to evaluate the renal protective effects of Losartan in patients with NIDDM & nephropathy, Phase III - IV, Merck 1997.
33. Correlation of blood glucose with iontophoretic extraction using the GlucoWatch in subjects with diabetes. Phase II Cygnus 1997.
34. Evaluation of the Glucometer DEX Stripless Monitoring Systems. Phase I - Bayer Diagnostics 1997.
35. Evaluation of a reduced pain blood sampling device. Phase I - Mercury Diagnostics 1997.

36. 28-week multicenter, controlled, randomized, open-label clinical trial comparing HOE-901 insulin with NPH human insulin in subjects with type 1 diabetes (HOE-901/3004). Phase III-Hoechst Marion Roussel, 1997.
37. 28-week multicenter, controlled, randomized, open-label clinical trial comparing HOE-901 insulin with NPH human insulin in subjects with type 2 diabetes (HOE-901/3006). Phase III-Hoechst Marion Roussel, 1997.
38. 16-week multicenter, controlled, randomized, open-label clinical trial comparing HOE 901 insulin and NPH human insulin in subjects with type 1 diabetes treated with insulin Lispro (HOE 901/3005). Phase III-Hoechst Marion Roussel, 1997.
39. An Open-Label, Subject-Controlled Clinical Study of Mercury Diagnostics Blood Glucose Measurement System ("Mercury Gold Systems"). Phase III Mercury Diagnostics, 1997.
40. Clinical Evaluation of Extremely Small Blood Volume Glucose Test Strips which Fill Capillary Blood from Arm Lancet Stick, TheraSense, Phase II, 1998.
41. Insulin Delivery Using a New Lilly 3.0 mL Disposable Pen Device, Protocol F3Z-US-IOHE Phase IV, Eli Lilly, 1998 - 2001.
42. Efficacy & Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 1 Diabetes Mellitus: A Six-month, Outpatient, Parallel Comparative Trial, Protocol 217-106, Phase III, Pfizer, 1998 - 2003.
43. Efficacy & Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus: A Six-month, Outpatient, Parallel Comparative Trial, Protocol 217-108, Phase III, Pfizer, 1998 - 2003.
44. Evaluating Insulin Syringe Brand Preference Among Consumers: A Multi-Center Study, Protocol BDCHC-DHC-98-23, Phase IV, Becton-Dickenson, 1999.
45. Repaglinide (Prandin) Combined with Bedtime Insulin NPH (Novolin N) in Comparison to Insulin in any Mixture Twice a Day for the Treatment of Type 2 Diabetes Patients Previously On Insulin Monotherapy; a Randomized Open-Label Study, Protocol AGEE-2022, Phase IV, Novo Nordisk, 1999.
46. Preliminary Evaluation of the Kumetrix, Inc. Minimally Invasive Glucose Test; Elements of Pain Perception, Needle Breakage, Blood Volume, Glucose Analysis, Development Study, 1999.
47. A Multicenter, Randomized, Double-Blind, Parallel-Group, Clinical Evaluation of Oral GI262570 Sodium Tablets (2.5 mg, 5 mg and 7.5 mg GI262570) in Combination With Metformin For 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on a Maximum Dose of Metformin, PPA300002, Phase III, GlaxoWellcome, 1999.
48. OTC Clinical Evaluation of DRx<sup>®</sup> HbA1c, Protocol 083099-HbA1c, Metrika, Inc., 1999.
49. A Study To Compare The Performance Of The Glucowatch<sup>®</sup> Automatic Glucose Biographer Using Autosensors From Two Different Manufacturing Sites In Subjects With Diabetes Mellitus. GMS-PAC-052, Cygnus, Inc., 2000.
50. "Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (Octave), BMS, Phase III, 2000.
51. Long Term Safety of EXUBERA (inhaled insulin): Extension of Therapy in Subjects with Type 1 or Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials. Pfizer Inc. 2000 -
52. Prospective Evaluation of the New HFE-71L-14457 Lubrication with 29 Gauge, 12-7mm, ½ cc and 3/10 cc Insulin Syringes in Adults. Becton Dickinson & Company, 2001.
53. 12-Week, Multinational, Multicenter, Controlled, Open, 1:1:1 Randomized, Parallel Clinical Trial to Assess Noninferiority Between Pre- and Post-Meal Administration of HMR 1964 and Pre-Meal Regular

Human Insulin in Subjects with Type 1 Diabetes Mellitus Receiving Insulin Glargine as the Basal Insulin Therapy. Aventis Pharmaceuticals, Inc. 2001.

54. Systolic and Pulse Pressure Hemodynamic Improvement by Restoring Elasticity: The Sapphire Study. Alteon, Inc. Phase II, Alteon, Inc, Phase II, 2001 - 2003.
55. Systolic and Pulse Pressure Hemodynamic Improvement by Restoring Elasticity: The Sapphire Study-Extension Safety Study, ALT-711-0215, Alteon, Inc. Phase II, 2002 - 2003.
56. KOS Pharmaceuticals Inc. & Dupont Pharmaceuticals Company, "The IMPACT Study-The Impact of Medical Subspecialty on Patient Compliance to Treatment" ICON Clinical Research, Inc. 2001.
57. Point-of-Care %HbA1c Testing- A1cNow™, METRIKA, INC. 2001 - 2003.
58. A Market Research Study of the Glucowatch® Automatic Glucose Biographer for Use to Detect Trends and Track Patterns in Glucose Levels in Adults with Diabetes. Cygnus™ 2001.
59. Preliminary Evaluation of the Phoenix Bioscience IPD Sampling System and Glucose Test; Elements of Pain Perception, Blood Volume, Glucose Analysis, PHOENIX BIOSCIENCE, INC 2002 -
60. GOAL A1c Impact of Point-Of-Care vs. Laboratory Testing Of Hemoglobin A1c (HbA1c) And Intense vs. Standard Monitoring Of Titration Algorithm Adherence On Glycemic Control In Type 2 Diabetes Subjects, Who Are Inadequately Controlled On Oral Anti-Hyperglycemic Therapy, And Starting Lantus® (Insulin Glargine [rDNA Origin] Injection): A 2X2, Randomized, Open-Label Trial. Aventis Pharma 2002 - 2003.
61. A Phase 3B, Multicenter, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Insulin Therapy, Amylin 2003 -
62. Evaluation of the Phoenix Bioscience IPD Sampling System and Glucose Test; Elements of Pain Perception, Blood Volume, Glucose Analysis, PHOENIX BIOSCIENCE, INC 2003.
63. A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia, Merck 2003 -2004.
64. A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-550 in the Treatment of Patients with Type 2 Diabetes Mellitus, Takeda, 2003 - 2005.
65. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy, Novartis 2004 - 2006, Phase III.
66. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy, Novartis 2004 - 2006, Phase III.
67. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Pioglitazone 45 mg qd in Patients with Type 2 Diabetes Inadequately Controlled with Thiazolidinedione Monotherapy, Novartis 2004 - 2006, Phase III.
68. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Pioglitazone 45 mg qd in Patients with Type 2 Diabetes Inadequately Controlled with Thiazolidinedione Monotherapy, Novartis 2004 - 2006, Phase III.
69. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy to Glimepiride in Patients with

- Type 2 Diabetes Inadequately Controlled with Sulfonylurea Monotherapy, Novartis 2004 - 2006, Phase III.
70. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in to Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled with Sulfonylurea Monotherapy, Novartis 2004 - 2006, Phase III.
  71. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 50 mg bid to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Treated with Insulin, Novartis 2004 - 2006.
  72. A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 50 mg bid to Placebo as Add-on Therapy in Patients with Insulin, Novartis 2004 - 2006.
  73. An International Prospective Observational Registry in Subjects at Risk of Atherothrombotic Events. The REACH REGISTRY, Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership, 2004 - 2006.
  74. Protocol-EFC5826 (CRESCENDO)-Randomized, multinational, Multicenter, double-blind, placebo-controlled, two-arm parallel group trial of Rimonabant 20-mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors, Sanofi-Aventis, 2006 - Phase III.
  75. A Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized Losartan therapy and optimal antihypertensive therapy in patients with hypertension and Type 2 diabetes mellitus, Novartis, 2006 -, Phase III. Protocol number CSPP100C2201.
  76. Protocol #: PHS1149-PROT201, Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Examine Safety and Establish Proof of Concept with PHX1149 in Patients with Type 2 Diabetes Mellitus, Phenomix Corporation 2006 -
  77. Trial ID: NN304-1720. Impact of a Self-Adjusted Titration Guideline in Subjects with Type 2 Diabetes Mellitus: A 6-Month, Multicenter, Open-Label, Randomized, Parallel-Group, Treat-to-Target of the Efficacy and Safety of Levemir<sup>®</sup> (insulin detemir [rDNA origin] injection). The PREDICTIVE<sup>™</sup> 303 Study, Novo Nordisk, 2006 -, Phase IV.
  78. An 8-week, Multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertension, Novartis 2006 -
  79. Protocol ACD06-072 User Evaluation of the FreeStyle Navigator<sup>®</sup> Continuous Glucose Monitoring System, Abbott Diabetes Care, 2007.
  80. A Phase II, randomized, double-blind, parallel-design study comparing efficacy and safety of VI-0521 to placebo in the Glycemic management of obese diabetic adults, Vivus, Inc, 2007 - 2009.
  81. Protocol HRA26-755A2-3, Validation Study for Two Measures regarding Insulin Therapy (EAITQ and EWITQ), Eli Lilly, 2007.
  82. Protocol VP-000077, Feasibility of Finesse to be as Effective and Safe but More Acceptable to Diabetes Patients Compared to Multiple Daily Injections with Pen Devices/Syringes for Bolus Prandial Insulin Dosing, Calibra Medical, Inc. 2010.
  83. V4006: Effectiveness of V-Go<sup>™</sup> for Patients with Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE) 2011.

84. Active: CBX129801-DN-201, A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-peptide, in Type 1 Diabetes Mellitus subjects with Mild to Moderate Diabetic Peripheral Neuropathy.

## **SPEAKING**

Dr. Bohannon has been speaking internationally since 1978. Venues have included Germany, Canada, Italy, Korea, Taiwan, Thailand, the Philippines, the United Arab Emirates, India, Mexico, Singapore and the United Kingdom. She was a Consultant to the Ministry of Health, Abu Dhabi, United Arab Emirates from 1995 - 2006.

She has lectured yearly for 1 or 2 weeks in the UK, at the invitation of the Postgraduate Tutor program of the National Health Service as well as other sponsors, throughout England, Scotland and Ireland. She also has been keynote speaker at many symposia in the United States.

## **BIOTECH AND ANALYST CONSULTANCIES**

Primary Insight (a unit of Bear Stearns, a leading Wall Street investment bank) 2006 - current

Society of Industry Leaders (Standard and Poore's Vista) 2005 - current

MEDACORP 2004 - current

ePocrates Honors Advocate 2006 - current

Clinical Advisors 2004 - current

Gerson Lehrman Group 2002 - current